Cogent Biosciences
COGT
144 hedge funds and large institutions have $547M invested in Cogent Biosciences in 2023 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 61 increasing their positions, 30 reducing their positions, and 24 closing their positions.
103% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 30
99% more call options, than puts
Call options by funds: $1.3M | Put options by funds: $652K
50% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 24
7% more funds holding
Funds holding: 135 → 144 (+9)
1.77% more ownership
Funds ownership: 106.31% → 108.08% (+1.8%)
38% less capital invested
Capital invested by funds: $886M → $547M (-$339M)
71% less funds holding in top 10
Funds holding in top 10: 7 → 2 (-5)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$33.6M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$27.9M |
| 3 |
Millennium Management
New York
|
+$20.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.07M |
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$62.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$16.4M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$12.6M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$12.4M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.1M |
COGT Hedge Fund Activity: Q4 2023 in Review
144 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q4 2023, worth a combined $547M — down 38% from $886M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new COGT positions and 24 closed out — a net gain of 12 holders — while 61 added to existing stakes and 30 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $33.6M. The largest seller was RA Capital Management, exiting entirely with an estimated $62.6M sold.
- 144 institutional investors held Cogent Biosciences (COGT) as of Q4 2023, up from 135 in Q3 2023.
- Funds reported $547M of Cogent Biosciences stock for Q4 2023, down 38% quarter-over-quarter.
- 36 funds opened new Cogent Biosciences positions in Q4 2023 and 24 closed out, a net change of +12 holders.
- The largest Cogent Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $33.6M added.
- The largest Cogent Biosciences seller in Q4 2023 was RA Capital Management, an estimated $62.6M sold.
Based on aggregated 13F filings for Q4 2023.